Vyome (HIND) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vyome (HIND) has outperformed Quantum Biopharma (QNTM) over the past year, losing 75.9% versus a loss of 77.6%. Over five years, QNTM leads with a -98.5% price change compared with -100.0% for HIND. Vyome is the larger company by market cap ($8.4 million vs $8.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HIND | QNTM |
|---|---|---|
| Share price | $1.20 | $1.29 |
| Market cap | $8.42M | $8.29M |
| 1-day change | -17.24% | -9.15% |
| YTD return | -65.12% | -82.33% |
| 1-year return | -75.90% | -77.60% |
| 5-year return | -100.00% | -98.51% |
| P/E ratio (TTM) | 0.25 | — |
| EPS (TTM) | $4.77 | $-3.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $319.71K | — |
| Revenue growth (YoY) | +24.43% | — |
| Net income (latest FY) | $-10.26M | — |
| Gross margin | 68.43% | — |
| Operating margin | -3269.35% | — |
| Net margin | -3209.75% | — |
| 52-week high | $5.88 | $12.42 |
| 52-week low | $1.20 | $1.26 |
| Distance from 52-week high | -79.59% | -89.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +635.83% | +851.16% |
| Average volume | 13.92K | 148.83K |
| Shares outstanding | 7.02M | 6.43M |
| Employees | 9 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Vyome
HIND stock →Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
HIND vs QNTM FAQ
Which is bigger, Vyome or Quantum Biopharma?
Vyome (HIND) is larger, with a market capitalization of $8.42M compared with $8.29M for Quantum Biopharma (QNTM).
Which stock has performed better over the past year, HIND or QNTM?
HIND returned -75.90% over the past 12 months, compared with -77.60% for QNTM (price return, excluding dividends). Past performance does not predict future results.
Are Vyome and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.